LONDON, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that US patent US 11,098,121 and European patent EP3347039B have been granted. The patents cover a method of identifying cancer patients that are likely to respond to a checkpoint inhibitor (CPI) by determining the total number of clonal neoantigens or the ratio of clonal to subclonal neoantigens in patients’ cancer cells. Clonal neoantigens are neoantigens present on all tumor cells and absent from healthy tissue.
The patents are based on data showing that patients with higher numbers of clonal neoantigens respond better to checkpoint inhibitor therapies1. These initial findings have been confirmed in later studies showing that clonal tumor mutation burden was the strongest predictor of CPI response across seven different tumor types and three different classes of CPIs in over 1,000 CPI-treated patients2.
“This is another important step in building our intellectual property position around our precision T cell therapy platform, supporting our approach of targeting clonal neoantigens that we identify with our proprietary PELEUS® bioinformatics platform,” said Dr Iraj Ali, CEO of Achilles Therapeutics. “This adds to the growing body of data underpinning our thesis that clonal neoantigens are the best targets in solid tumor therapy. Our technology allows us to prospectively determine and target all of a patient’s unique, clonal neoantigens and expand the clonal neoantigen-reactive T cells, or cNeT, and ensure that these reactivities are present in the final medicinal product with use of our potency release assay.”
The patents are assigned to Cancer Research Technology and licensed exclusively to Achilles in certain fields. The inventors include three of Achilles’ co-founders, Dr Sergio Quezada, Chief Scientific Officer, Dr Karl Peggs, Chief Medical Officer, and Professor Charles Swanton, a Royal Society Napier Professor of Cancer and Chief Clinician at Cancer Research UK, as well as Group Leader at the Francis Crick Institute and UCL.
“Achilles continues to advance their development of precision T cell therapies for solid tumor cancers. These patents are illustrative of the pioneering work that Achilles and Cancer Research UK have done in the field of clonal neoantigens,” said Tony Hickson, Chief Business Officer of Cancer Research UK.
1. McGranahan et al 2016, Science: https://science.sciencemag.org/content/351/6280/1463
2. Litchfield et al 2021, Cell: https://www.cell.com/cell/pdf/S0092-8674(21)00002-7.pdf